Is BioHarvest Sciences Inc. Common Stock (BHST) a Buy, Sell, or Hold?
BioHarvest Sciences Inc. Common Stock
NASDAQ:BHST
$2.79 USD
$0.02 (0.72%)
- Volume
- 31.84K
- Average Volume
- 29.77K
- Market Capitalization
- $48.34M
- P/E Ratio
- -4.50
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $12.80
- Year Low
- $2.70
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.96
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Ilan Sobel |
| Industry | Agricultural Inputs |
| Sector | Basic Materials |
| Current Symbol | BHST |
| CUSIP | 09076J207 |
| CIK | 0001723464 |
| Web | https://www.bioharvest.com |
| Phone | (604) 622-1186 |
| Currency | USD |
| Employees | 89 |
| Country | CA |
Liquidity
| Debt-to-Equity Ratio | 0.71 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.96 |
| Quick Ratio | 2.44 |
| Cash Ratio | 2.00 |
Sales & Book Value
| Annual Sales | $34.51M |
| Price / Sales | 1.38 |
| Cash Flow | -0.43 |
| Price / Cash Flow | -4.96 |
| Price / Book | 2.75 |
Price Target and Rating
| Average Stock Price Forecast | $10.00 |
| High Stock Price Forecast | $10.00 |
| Low Stock Price Forecast | $10.00 |
| Forecast Upside/Downside | -72.10% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 1 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.6 |
| Trailing P/E Ratio | -4.50 |
| PEG Ratio | 0.14 |
| P/E Growth | 0.14 |
| Net Income | $-11.14M |
| Net Margin | -32.54% |
| Pretax Margin | -32.30% |
| Return on Equity | -88.01% |
| Return on Assets | -25.11% |
Financials Score
| AltmanZ Score | -1.48 |
| Piotroski Score | 3.00 |
| Working Capital | 18.74M |
| Total Assets | 45.56M |
| Ebit | -8.34M |
| Market Cap | 46.78M |
| Total Liabilities | 22.54M |
Poll Results
About BioHarvest Sciences Inc. Common Stock (NASDAQ:BHST) Stock
BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Is ... rael and the United States, with its corporate base in Vancouver, Canada.
2026-07-13 08:00:00
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 13, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will participate in a fireside chat at the upcoming Maxim Health, Wellness & Longevity Conference, to be held virtually on July 22, 2026. Presentation Details: Date/Time: Wednesday, July 22, 2026 at 10:00 a.m.
BioHarvest Sciences to Present at the 2026 BIO International Convention
2026-06-18 07:30:00
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will present at the upcoming BIO International Convention, to be held on June 22-25, in San Diego, California. Presentation Details: Session: Company Presentation Date/Time: Wednesday, June 24, 11:45 AM Location: Theater 3 BioHarvest Sciences' presentation will showcase its proprietary Botanical Synthesis™ platform, which enables the production of plant-derived compounds with pharmaceutical-grade precision, consistency, and commercial scalability, opening new possibilities in drug discovery, active pharmaceutical ingredients, and next-generation therapeutics.
BioHarvest Sciences and Tate & Lyle expand sweetener development program
2026-05-19 08:41:38
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has expanded its collaboration with Tate & Lyle PLC (LSE:TATE) to broaden the scope of their joint sweetener development program to include multiple plant-based sweetener molecules. The expanded partnership builds on an agreement signed in 2024 and follows what the companies described as strong technical progress in developing sweetening solutions for food and beverage manufacturers.
2026-05-18 07:00:00
Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories. Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced the expansion of its collaboration with Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, broadening the scope of their joint sweetener development program to include multiple plant-based sweetener molecules.
BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcript
2026-05-14 13:50:47
BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcript
BioHarvest Sciences Q1 Earnings Call Highlights
2026-05-14 10:09:45
BioHarvest Sciences NASDAQ: BHST reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer VINIA products business and its contract development and manufacturing organization, or CDMO, platform.
BioHarvest Sciences Q1 revenue climbs as it expands botanical synthesis pipeline
2026-05-14 08:53:27
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported an 8% jump in first quarter revenue as the company advanced several contract development and manufacturing organization (CDMO) projects and expanded its direct-to-consumer wellness business. The company posted first quarter revenue of $8.5 million, up from $7.9 million a year earlier, while maintaining its full-year revenue guidance range of $42 million to $48 million.
BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Beats Revenue Estimates
2026-05-14 08:11:06
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.
Frequently Asked Questions
-
What is the current BioHarvest Sciences Inc. Common Stock (BHST) stock price?
-
BioHarvest Sciences Inc. Common Stock(NASDAQ:BHST) stock price is $2.79 in the last trading session. During the trading session, BHST stock reached the peak price of $12.8 while $2.7 was the lowest point it dropped to. The percentage change in BHST stock occurred in the recent session was 0.72% while the dollar amount for the price change in BHST stock was $0.02.
-
BHST's industry and sector of operation?
-
The NASDAQ listed BHST is part of Agricultural Inputs industry that operates in the broader Basic Materials sector.
-
Who are the executives of BHST?
-
Jared Turner | Chief Sales Officer
Yoheved Hagay | Co-Founder & CTO
Ilana Belzer | Chief Operating Officer
Malkit Azachi | Vice President of Research & Development
Zaki Rakib | Co-Founder, CEO, Executive Chairman & President -
How many employees does BHST have?
-
Number of BHST employees currently stands at 89. BHST operates from 1140-625 Howe Street, Vancouver, BC V6C 2T6, CA.
-
Link for BHST official website?
-
Official Website of BHST is: https://www.bioharvest.com
-
How do I contact BHST?
-
BHST could be contacted at phone #(604) 622-1186 and can also be accessed through its website. BHST operates from 1140-625 Howe Street, Vancouver, BC V6C 2T6, CA.
-
How many shares of BHST are traded daily?
-
The average number of BHST shares traded daily for last 3 months was 29.77K.
-
What is the market cap of BHST currently?
-
The market value of BHST currently stands at $48.34M with its latest stock price at $2.79